BIZENGRI (zenocutuzumab-zbco)
ANTINEOPLASTIC MONOCLONAL ANTIBODIES·NEUREGULIN 1 GENE FUSION POSITIVE PANCREATIC ADENOCARCINOMA·+2
SANOFI/PARTNER
Indication
Neuregulin 1 gene fusion positive pancreatic adenocarcinoma
Neuregulin 1 (NRG1) gene fusion–positive pancreatic adenocarcinoma is an aggressive malignancy arising from the exocrine tissue of the pancreas, characterized by chromosomal rearrangements involving the *NRG1* gene. Read more about Neuregulin 1 gene fusion positive pancreatic adenocarcinoma
1 drugs 1 manufacturers
Drugs that treat it
Common Neuregulin 1 gene fusion positive pancreatic adenocarcinoma therapies.
Filter & compare in the drug finder →Opens the drug finder with Neuregulin 1 gene fusion positive pancreatic adenocarcinoma preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonNeuregulin 1 (NRG1) gene fusion–positive pancreatic adenocarcinoma is an aggressive malignancy arising from the exocrine tissue of the pancreas, characterized by chromosomal rearrangements involving the *NRG1* gene.
In these tumors—which disproportionately occur within the subset of pancreatic cancers lacking canonical *KRAS* mutations—the resulting chimeric fusion proteins retain the epidermal growth factor–like domain of NRG1.
This chimeric ligand aberrant-activates HER3 (ERBB3) and induces HER2/HER3 heterodimerization, triggering persistent downstream oncogenic signaling via the MAPK and PI3K/AKT pathways that drives unchecked cell survival and tumor growth.
Patients typically present with symptoms of advanced pancreatic malignancy, such as abdominal or back pain, obstructive jaundice, unexplained weight loss, and severe digestive dysfunction.
- oncokb.org
Neuregulin 1 (NRG1) gene fusion–positive pancreatic adenocarcinoma is an aggressive malignancy arising from the exocrine tissue of the pancreas, characterized by chromosomal rearrangements involving the *NRG1* gene
- aacrjournals.org
Neuregulin 1 (NRG1) gene fusion–positive pancreatic adenocarcinoma is an aggressive malignancy arising from the exocrine tissue of the pancreas, characterized by chromosomal rearrangements involving the *NRG1* gene In these tumors—which disproportionately occur within the subset of pancreatic cancers lacking canonical *KRAS* mutations—the resulting chimeric fusion proteins retain the epidermal growth factor–like domain of NRG1
- aacr.org
Neuregulin 1 (NRG1) gene fusion–positive pancreatic adenocarcinoma is an aggressive malignancy arising from the exocrine tissue of the pancreas, characterized by chromosomal rearrangements involving the *NRG1* gene This chimeric ligand aberrant-activates HER3 (ERBB3) and induces HER2/HER3 heterodimerization, triggering persistent downstream oncogenic signaling via the MAPK and PI3K/AKT pathways that drives unchecked cell survival and tumor growth Patients typically present with symptoms of advan...
- onclive.com
In these tumors—which disproportionately occur within the subset of pancreatic cancers lacking canonical *KRAS* mutations—the resulting chimeric fusion proteins retain the epidermal growth factor–like domain of NRG1 This chimeric ligand aberrant-activates HER3 (ERBB3) and induces HER2/HER3 heterodimerization, triggering persistent downstream oncogenic signaling via the MAPK and PI3K/AKT pathways that drives unchecked cell survival and tumor growth
- oup.com
In these tumors—which disproportionately occur within the subset of pancreatic cancers lacking canonical *KRAS* mutations—the resulting chimeric fusion proteins retain the epidermal growth factor–like domain of NRG1
- nih.gov
This chimeric ligand aberrant-activates HER3 (ERBB3) and induces HER2/HER3 heterodimerization, triggering persistent downstream oncogenic signaling via the MAPK and PI3K/AKT pathways that drives unchecked cell survival and tumor growth
Personalize your experience
Follow Neuregulin 1 gene fusion positive pancreatic adenocarcinoma and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.